United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
NASDAQ:UTHR
Price:
238.485 USD
1.98%
Updated:
Apr 29, 2024
United Therapeutics Corp
Cash from Operating Activities
|
United Therapeutics Corp
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Cash from Operating Activities
$978m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is United Therapeutics Corp's Cash from Operating Activities?
Cash from Operating Activities
978m
USD
978m
USD
Based on the financial report for Dec 31, 2023, United Therapeutics Corp's Cash from Operating Activities amounts to 978m USD.
What is United Therapeutics Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
9%
9%
Over the last year, the Cash from Operating Activities growth was 22%. The average annual Cash from Operating Activities growth rates for United Therapeutics Corp have been 9% over the past three years , 5% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
